Nifty Pharma News and Updates

Name: Latest research reports of Biocon Ltd. authored by Axis Direct and published by - Trendlyne research reports.
Item: Biocon Ltd.
Rating: 5
Author: Axis Direct

Keep track of all breaking news on Nifty Pharma from all sources in a single place.

Load latest

Lupin Ltd.

12 Aug 2025

1937.30

-1.84%

Lupin partners with Sandoz to commercialise ranibizumab in different markets

Business Line

Sandoz will oversee commercialisation of the product, while Lupin will be responsible for manufacturing and regulatory submissions

Lupin Ltd. has an average target of 2326.00 from 8 brokers.

Wockhardt Ltd.

12 Aug 2025

1429.20

-2.11%

Wockhardt Eyes Healthy Bottom Line' In Coming Quarters Amid US Tariff Concerns

NDTV Profit

The company recently announced its exit from the loss-making US generics business.

Wockhardt Ltd. is trading below all available SMAs

Ipca Laboratories Ltd.

11 Aug 2025

1323.20

0.77%

to see Rapid results content

Biocon Ltd.

11 Aug 2025

347.75

-1.28%

Biocon shares slip 3% as Q1 results miss estimates; should you sell?

Business Standard

Biocon shares fell 3 per cent after it reported a 95.2 per cent decline in net profit in Q1FY26

Biocon Ltd. is trading below all available SMAs

Biocon Ltd.

11 Aug 2025

347.75

-1.28%

Result Update:Biocon

Buy: Biocon Ltd.

Target

Axis Direct

We maintain our BUY rating on the stock with a target price of Rs 380/share, implying an 11% upside potential from the CMP.

Biocon Ltd. is trading below all available SMAs

Mankind Pharma Ltd.

09 Aug 2025

2456.30

0.34%

Mankind Pharma Confident GLP-1 Won't Dent Anti-Diabetic Portfolio Growth

NDTV Profit

Even if shifts occur within the anti-diabetes segment, such as therapies moving from the top to the bottom of the market pyramid, Mankind expects to remain stable.

Number of FII/FPI investors increased from 640 to 648 in Jun 2025 qtr.

Biocon Ltd.

09 Aug 2025

347.75

-1.28%

Margin pressure persists

Sell: Biocon Ltd.

Target

ICICI Securities Limited

Biocon’s Q1FY26 performance was marred by operating cost of new facilities for generic division and lower-thananticipated margins in biologics division.